Dive into the full 2024 Sustainability Report at elaia.com/esg.

The continuous development of science and technology continues to drive better understanding of the human body. We partner in the development of human health outcomes, from drug discovery, new treatment options, and technology to assist existing healthcare practices.

Portfolio Case Study: HEPHAISTOS-Pharma

HEPHAISTOS-Pharma is an immunotherapy startup that is designing and developing sole-in-class engineered immune sensor modulators to tackle the biggest challenge in oncology: Tumor resistance to immunotherapy.

ONCO-Boost is the first product from HEPHAISTOS-Pharma’s platform. It stimulates the patients’ own immune system, strengthening both innate and adaptive immune systems, to reshape tumor Micro-Environment. ONCO-Boost can work both as a single agent and in combination with established immunotherapies that do not work against cold tumours, boosting their efficacy to breakthrough levels. Thanks to its intravenous administration, ONCO-Boost is the first immunostimulant to demonstrate simultaneous efficacy against both primary tumours and metastases.

Portfolio Case Study: Hema.to

Hema.to is a deep tech AI company solving measurement of blood cell data and thereby make an outsised and lasting impact on immune medicine: they want to make sure every patient gets the right treatment at the right time for their unique immune systems.